Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, commercialization and manufacture of pharmaceutical products, based on proprietary DepoFoam drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. EXPAREL In 2011, the United States Food and Drug Administration, or FDA, approved New Drug Application (NDA), for its main product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia for up to 72 hours. EXPAREL addresses a significant unmet medical need for a long-acting non-opioid postsurgical analgesic, resulting in simplified postsurgical pain management and reduced opioid consumption, leading to improved patient outcomes and enhanced hospital economics. EXPAREL provides continuous and extended postsurgical analgesia for up to 72 hours and reduces the consumption of opioid medications. Other Products DepoCyt(e): DepoCyt(e) is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine utilizing DepoFoam technology. DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. DepoCyt(e) is dosed once every two weeks in an outpatient setting. DepoCyt(e) was granted accelerated approval by the FDA in 1999 and full approval in 2007. Strategy The company’s goal is to be a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products principally for use in hospitals and ambulatory surgery centers. It plans to achieve this by: commercializing EXPAREL in the United States for postsurgical analgesia by infiltration; building a streamlined commercial organization concentrating on major hospitals and ambulatory surgery centers in the United States and targeting surgeons, anesthesiologists, pharmacists and nurses; demonstrating the economic benefits of EXPAREL, working directly with managed care payers, quality improvement organizations, Key Opinion Leaders, or KOLs, in the field of postsurgical pain management and leading influence hospitals in conducting Phase 4 retrospective and prospective trials and drug utilization evaluations; servicing the commercial audiences that are rapidly adopting EXPAREL in local infiltration procedures; obtaining FDA approval for nerve block indication for EXPAREL; leveraging the development success of EXPAREL in the animal health market through commercial partner for Bupivacaine Liposome Injectable Suspension to serve the companion animal market; manufacturing all DepoFoam-based products, including EXPAREL, in facilities compliant with current Good Manufacturing Practices, or cGMP; continuing to expand marketed product portfolio through development of additional DepoFoam-based hospital products utilizing a 505(b)(2) strategy; and continuing research and development partnerships to provide DepoFoam-based products to enhance the duration of action and patient compliance for partner products. History Pacira Pharmaceuticals, Inc. was founded in 2006.
pacira pharmaceuticals inc
(PCRX:Consolidated Issue Listed on NASDAQ Global Select )
5 Sylvan Way
Parsippany, NJ 07054
|Akorn Inc||$53.81 USD||+0.34|
|Cumberland Pharmaceuticals Inc||$6.13 USD||+0.24|
|Durect Corp||$1.05 USD||-0.02|
|Halyard Health Inc||$46.04 USD||-0.77|
|Teleflex Inc||$121.69 USD||+0.47|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PACIRA PHARMACEUTICALS INC, please visit www.pacira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.